ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Farnesoid x Receptor Deficiency Promotes Hepatocytic Injury in Cyp2c70-Deficient Mice With a Human-Like Bile Acid Composition.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Farnesoid x Receptor Deficiency Promotes Hepatocytic Injury in Cyp2c70-Deficient Mice With a Human-Like Bile Acid Composition.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
BACKGROUND AND
aimsLoss-of-function mutations in bile acid (BA)-activated farnesoid x receptor (FXR/NR1H4) cause severe neonatal liver pathology in humans, earlier referred to as progressive familial intrahepatic cholestasis type 5 (PFIC5). However, Fxr-deficient mice do not develop early-onset liver disease, possibly due to the predominance of hydrophilic muricholic acids (MCAs) in their BA pool. Mice lacking Cyp2c70 display a human-like BA composition, lacking MCAs. This study aimed to evaluate whether Fxr/Cyp2c70-double knockout (DKO) mice recapitulate the pathophysiology of human FXR-deficiency.
methodsBA metabolism and liver pathology were assessed in wild-type (WT), Fxr-knockout (KO), Cyp2c70-KO and DKO mice of both sexes.
resultsFxr-deficiency markedly reduced the amounts of bile salt export pump (BSEP/ABCB11), but did not affect biliary BA secretion. DKO mice showed exacerbated hepatocytic injury and inflammation compared to Fxr-KO mice of both sexes. Surprisingly, despite higher alanine aminotransferase levels that indicate hepatocellular damage, female DKO mice showed much less liver fibrosis and ductular reactions than female Cyp2c70-KO mice. Gene Set Enrichment Analysis suggested that epithelial-mesenchymal transition was upregulated in Cyp2c70-KO livers compared to WT mice but downregulated particularly in livers of female DKO mice compared to Cyp2c70-KO. Biliary BA hydrophobicity was increased by the deletion of Cyp2c70, yet reduced by simultaneous absence of Fxr in female mice.
conclusionsFxr/Cyp2c70-DKO mice exhibit more severe hepatocytic injury than Fxr-KO mice, mirroring the clinical phenotype of FXR deficiency. These data highlight the importance of studying the aetiology of cholestatic liver diseases in the context of a human-like BA composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.